| Date | Title | Description |
| 31.07.2026 | CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial | HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership.
At ... |
| 10.07.2026 | FDA to Rule July 17 on Gedatolisib, First Targeted Therapy for PIK3CA Wild-Type Breast Cancer | By John Bright
Published: Jul 10 2026, 4:19 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 29.06.2026 | Enhertu approved in EU for HER2+ solid tumours | Enhertu approved in EU for HER2+ solid tumours
Mon, Jun 29, 2026 08:41 CET Report this content
29 June 2026
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously t... |
| 15.06.2026 | Truqap approved in US for prostate cancer | Truqap approved in US for prostate cancer
Mon, Jun 15, 2026 08:00 CET Report this content
15 June 2026
Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cance... |
| 29.05.2026 | No Smoker Left Behind: Research-backed smoking cessation as cancer care | Receiving a cancer diagnosis sometimes makes people think there is no point in quitting smoking, or that quitting will be too stressful to attempt during or after difficult cancer treatment. In reality, quitting is linked to better survival... |
| 26.05.2026 | Enhertu recommended in EU for HER2+ solid tumours | Enhertu recommended in EU for HER2+ solid tumours
Tue, May 26, 2026 08:00 CET Report this content
26 May 2026
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours
Bas... |
| 01.05.2026 | FDA ODAC recommends Truqap in prostate cancer | FDA ODAC recommends Truqap in prostate cancer
Fri, May 01, 2026 08:00 CET Report this content
01 May 2026
Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
ODAC overwhelming majorit... |
| 01.05.2026 | Hidden Barriers Could Contribute to Rising Colorectal Cancer Deaths in Adults Under 50 | The Colorectal Cancer Alliance is dedicated to ending the disease through Project Cure CRC.
Colorectal Cancer Alliance Urges Action for Women’s Health and Clinical Trials Awareness Month
Many young people and their doctors simply don't cons... |
| 24.04.2026 | Scans Can Reveal Hidden Prostate Cancer Progression | Maha Hussain, MD, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, was a co-author of the study.
A large analysis of two major clinical trials has found that the spread of prostate cancer can be dete... |
| 10.04.2026 | China’s Oricell raises $110M for carcinoma CAR-T plans ahead of IPO push | Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech seeks to go public.
The Shanghai-based company secured backing from the likes of E-Town Capital, Luxin Venture Capital... |
| 10.03.2026 | Registrational Phase III AMPLIFY trial: Target number of participants achieved | SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment o... |
| 20.12.2025 | Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards | SINGAPORE, Dec. 20, 2025 /PRNewswire/ -- Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights i... |
| 08.12.2025 | Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction Model | Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs
SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer d... |
| 05.09.2025 | Research exposes far-reaching toll of financial hardship on cancer patients | When someone mentions the word “toxicity” in relation to cancer treatment, they’re usually referring to the negative physical side effects and complications that can result from therapies like radiation and chemotherapy. But researchers at ... |
| 27.08.2025 | Cleveland Clinic Accelerates Clinical Trial Recruitment with Rollout of Dyania Health’s AI Platform Across Health System | Enterprise rollout follows successful pilot programs in cardiology, oncology and neurology
Through our collaboration with Cleveland Clinic, we are creating a new standard where AI enables faster connections between patients and potentially ... |
| 23.07.2025 | Healthcare’s Capacity Crisis: How AI Agents Enhance Clinician Productivity | Jeff Elton, Vice Chairman of Concert AI
America’s healthcare system is fighting battles on several fronts: surging patient needs across specialties, an aging clinical workforce, and escalating provider burnout. Projections indicate a shortf... |
| 17.07.2025 | Co-PSMA trial: Recruitment successfully completed | SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou... |
| 03.07.2025 | Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins
Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically signific... |
| 24.06.2025 | Datroway: A New Dawn for Lung Cancer Treatment in the U.S. | In a significant leap for cancer treatment, Datroway has received approval in the United States for patients battling advanced EGFR-mutated non-small cell lung cancer (NSCLC). This milestone, achieved on June 24, 2025, marks a pivotal momen... |
| 24.06.2025 | Datroway: A New Dawn in Lung Cancer Treatment | In a world where cancer looms large, hope often flickers like a candle in the wind. But on June 24, 2025, a new light emerged with the approval of Datroway (datopotamab deruxtecan) in the United States. This innovative therapy targets advan... |
| 24.06.2025 | Datroway approved in US for EGFRm lung cancer | Datroway approved in US for EGFRm lung cancer
Tue, Jun 24, 2025 08:00 CET Report this content
24 June 2025
Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Based on TROPION-Lu... |
| 19.06.2025 | The Dawn of Targeted Cancer Therapies: A New Era Beyond Chemotherapy | Cancer treatment is on the brink of a revolution. The days of chemotherapy, with its harsh side effects and systemic impact, may soon be numbered. Enter antibody-drug conjugates (ADCs), a class of targeted therapies that promise to deliver ... |
| 17.06.2025 | Targeted cancer drugs may replace chemo for some patients — and drugmakers say they’re getting closer | The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects.
There is still more work to be done to refine antibody-drug conjugates, but some are ... |
| 09.05.2025 | AI Study Challenges Fears of Racial Bias in Prostate Cancer Care | What You Should Know:
– Artera, a company developing multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the publication of a significant validation study in the JCO Clinical Cancer Inform... |
| 06.05.2025 | Calquence combination approved in EU for 1L MCL | Calquence combination approved in EU for 1L MCL
Tue, May 06, 2025 08:02 CET Report this content
06 May 2025
Calquence plus chemoimmunotherapy approved in the EU
as first and only BTK inhibitor for 1st-line mantle cell lymphoma
Approval base... |
| 28.04.2025 | New Medicare program could cut drug cost–if patients enroll | PHILADELPHIA – Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000—until recently. Thanks to changes in Medicare Part D introduced by the Inflatio... |
| 15.04.2025 | Updated clinical guidelines provide clear recommendations on the use of Laser Interstitial Thermal Therapy (LITT) in patients with metastatic brain tumors and radiation necrosis | Updated clinical guidelines provide clear recommendations on the use of Laser Interstitial Thermal Therapy (LITT) in patients with metastatic brain tumors and radiation necrosis
Tue, Apr 15, 2025 08:30 CET Report this content
Clinical Laser... |
| 25.02.2025 | InfoBionic.Ai Advances Cardiac Monitoring to Assist Physicians in Women's Heart Care | IFB PRS 01
Women's cardiovascular health is shaped by unique risks, from hormonal changes to the impact of cancer treatments. Proactive monitoring and personalized care are essential. InfoBionic.Ai's MoMe ARC® delivers real-time cardiac ins... |
| 20.01.2025 | Dato-DXd approved in US for HR+ breast cancer | Dato-DXd approved in US for HR+ breast cancer
Mon, Jan 20, 2025 08:00 CET Report this content
20 January 2025
Datroway (datopotamab deruxtecan) approved in the US for patients with
previously treated metastatic HR-positive, HER2-negative br... |
| 17.01.2025 | Investigating New Treatments for Rare Skin Lymphomas | Timothy M Kuzel, MD, ’87 ’90 GME, clinical professor of Medicine in the Division of Hematology and Oncology, was a co-author of the study.
A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, accordi... |
| 25.12.2024 | AstraZeneca and Daiichi Sankyo Withdraw Lung Cancer Drug Application in EU: A Setback in Oncology Innovation | In a significant turn of events, AstraZeneca and Daiichi Sankyo have voluntarily withdrawn their marketing authorization application for datopotamab deruxtecan (Dato-DXd) in the European Union. This decision, announced on December 24, 2024,... |
| 24.12.2024 | Dato-DXd NSQ NSCLC application withdrawn in EU | Dato-DXd NSQ NSCLC application withdrawn in EU
Tue, Dec 24, 2024 08:00 CET Report this content
24 December 2024
Datopotamab deruxtecan application in the EU for patients with advanced
nonsquamous non-small cell lung cancer voluntarily withd... |
| 13.12.2024 | The Heart of the Matter: Plant Proteins and Their Role in Cardiovascular Health | In a world where food choices shape our health and the environment, a recent Harvard study sheds light on the power of plant proteins. It’s a call to action, urging us to rethink our plates. The findings are clear: more plants, less meat. T... |
| 12.12.2024 | Navigating the ups and downs of the lymphoma journey | Listen to this article
Navigating the ups and downs of the lymphoma journey
7 min
New: You can now listen to articles.
This audio is generated by an AI tool.
A lymphoma diagnosis often leaves patients with deep uncertainty. In Singapore, th... |
| 06.12.2024 | Decreasing Fatigue in Patients with Advanced Breast Cancer | Acceptance and commitment therapy (ACT) significantly decreased fatigue interference and improved quality of life in patients with metastatic breast cancer six months after treatment, according to recent findings published in the Journal of... |
| 25.11.2024 | Truqap improved rPFS in advanced prostate cancer | Truqap improved rPFS in advanced prostate cancer
Mon, Nov 25, 2024 08:00 CET Report this content
25 November 2024
Truqap combination in PTEN-deficient metastatic hormone-sensitive
prostate cancer demonstrated statistically significant and c... |
| 19.11.2024 | Healing Through Innovation: The Future of Multiple Myeloma Treatment | Multiple myeloma is a formidable foe. It lurks in the shadows, often unnoticed until it strikes with debilitating symptoms. For many, like Patricia Wong, the journey begins with pain—severe back pain that disrupts life. This pain, a siren c... |
| 19.11.2024 | Recent breakthroughs expand treatment options for multiple myeloma | Listen to this article
Recent breakthroughs expand treatment options for multiple myeloma
1 min
New: You can now listen to articles.
This audio is generated by an AI tool.
In 2022, Ms Patricia Wong’s life was disrupted when severe back pain... |
| 12.11.2024 | AstraZeneca and Daiichi Sankyo Forge Ahead with Datopotamab Deruxtecan Amid Regulatory Shifts | In the fast-paced world of oncology, AstraZeneca and Daiichi Sankyo are navigating the complex landscape of drug approval with their latest offering, datopotamab deruxtecan (Dato-DXd). This investigational drug is aimed at treating advanced... |
| 12.11.2024 | AstraZeneca's Bold Moves: New Approvals and Major Investments | AstraZeneca is making waves in the pharmaceutical world. The company recently submitted a new Biologics License Application (BLA) for datopotamab deruxtecan, a promising treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mu... |
| 12.11.2024 | Dato-DXd new BLA submitted, NSQ BLA withdrawn | Dato-DXd new BLA submitted, NSQ BLA withdrawn
Tue, Nov 12, 2024 08:00 CET Report this content
12 November 2024
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mu... |
| 11.11.2024 | Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting | DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced... |
| 23.10.2024 | The Houstonian Club Offers Tailored Fitness Options for Women Affected by Breast Cancer | Located in the heart of Houston, The Houstonian Club is a premier fitness and wellness center offering sessions with personal trainers who specialize in working with women affected by breast cancer.
According to the American Society of Clin... |
| 08.10.2024 | Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC | ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily f... |
| 26.09.2024 | Hong Kong Breast Cancer Registry Report No. 16 Press Conference: Analyze De Novo Metastatic Breast Cancer, Precise Staging Enhances Treatment | HONG KONG, Sept. 26, 2024 /PRNewswire/ -- The Hong Kong Breast Cancer Registry (HKBCR), run by the Hong Kong Breast Cancer Foundation (HKBCF), launched its 16th annual research report today. The report aimed to shed light on the comparison ... |
| 23.09.2024 | Final OS results reported for TROPION-Breast01 | Final OS results reported for TROPION-Breast01
Mon, Sep 23, 2024 08:00 CET Report this content
23 September 2024
Datopotamab deruxtecan final overall survival results reported in
patients with metastatic HR-positive, HER2-low or negative br... |
| 08.08.2024 | Balancing the right treatments for metastatic cancer | Cancer immunotherapy has had a significant impact on cancer treatment, transforming the landscape of oncology and providing hope for patients. Unlike traditional therapies such as chemotherapy and radiation, which target cancer cells direct... |
| 01.08.2024 | Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update | – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 –
– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
– Pivotal AUGME... |
| 01.07.2024 | Lynparza & Imfinzi positive CHMP in endometrial | Lynparza & Imfinzi positive CHMP in endometrial
Mon, Jul 01, 2024 08:00 CET Report this content
1 July 2024
Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advance... |
| 17.06.2024 | Imfinzi approved in the US for endometrial cancer | Imfinzi approved in the US for endometrial cancer
Mon, Jun 17, 2024 08:00 CET Report this content
17 June 2024
Imfinzi plus chemotherapy approved in the US for
mismatch repair deficient advanced or recurrent endometrial cancer
Approval base... |
| 11.06.2024 | Attorneys in Talc Cancer Litigation Discourage Voting for a Bankruptcy Plan That Will Strip Women of Personal Rights | Researched published last month concluded there is a significant link between genital talc use and an increased risk of ovarian cancer.
Lawyers who accept J&J's plan are disregarding docs showing J&J's bad conduct—evidence that, at ... |
| 08.06.2024 | Процесс старения и ключ к его торможению. О чем говорят генетические заболевания? | Так уж сложилось, что мой интерес к технологиям, продлению жизни, ЗОЖу и биохакингу брал начало в страхе смерти и панических атаках, что начались в 2011 году. Внезапное осознание смертности подстегивало как электрический разряд, побуждая уз... |
| 02.06.2024 | Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 31.05.2024 | Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer | TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.
Reported median radiographic progression-free survival (rP... |
| 31.05.2024 | New Lung Cancer Drug Halts Disease Progression Longer Than Ever Before | By John Lopez
Published May 31, 2024 11:22AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
A groundbreaking development in lung cancer treatment has emerged with the first trial ... |
| 24.05.2024 | Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024 | Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS |
| 23.05.2024 | Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024 | Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS |
| 16.05.2024 | Dr. Daniel Geynisman Named New Editor-in-Chief for JNCCN--Journal of the National Comprehensive Cancer Network | Chief of the Genitourinary Division for Fox Chase Cancer Center, and Member of two NCCN Guidelines Panels to oversee high-impact oncology research journal.
PLYMOUTH MEETING, Pa., May 16, 2024 /PRNewswire/ -- Daniel M. Geynisman, MD, is bein... |
| 03.04.2024 | Working with your hands is good for your brain – but typing on your phone doesn't really count | The human hand is a marvel of nature. No other creature on Earth, not even our closest primate relatives, has hands structured quite like ours, capable of such precise grasping and manipulation.
But we’re doing less intricate hands-on work ... |
| 19.03.2024 | Health | Operating in the red: Half of rural hospitals lose money, as many cut services | Jazmin Orozco Rodriguez | (TNS) KFF Health News
In a little more than two years as CEO of a small hospital in Wyoming, Dave Ryerse has witnessed firsthand the worsening financial problems eroding rural hospitals nationwide.
In 2022, Ryerse’... |
| 10.01.2024 | Navigating Cancer Achieves Record Success in 2023 with Milestones in Innovation, Research, and Financial Growth | Navigating Cancer's new mobile first patient portal and Health Tracker products drive increased patient engagement.
Our research shows that usage of ePROs delivers a better patient experience, reduces costs, and improves patient outcomes.”
... |
| 20.12.2023 | Pregnant cancer patients often have to terminate. Abortion pill restrictions could make that choice even harder | WASHINGTON — The patient had already made the agonizing decision to start chemotherapy to address her colon cancer, even though she was 30 weeks pregnant. Within a day, the decisions got harder: her colon perforated, and the pain was excruc... |
| 28.11.2023 | RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO) | YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced its two Phase II, open-label, multicenter, sing... |
| 08.11.2023 | Many Americans receive too much health care. That may finally be changing | The opioid crisis rocked America, bringing addiction and overdose into the spotlight. But it also highlighted the overtreatment of pain: Medical and dental providers alike overprescribed opioids after procedures and for chronic conditions. ... |
| 02.11.2023 | European Medicines Agency validates Pierre Fabre Laboratories' marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant ... | - BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC
- The application is based on results from the PHAROS study,[1] which showed an objective response ra... |
| 29.10.2023 | Liquid biopsy for cancer recurrence creates a new kind of patient-in-waiting | My husband’s cancer came back this summer after not being evident for almost two years.
With advances in cancer surveillance, we now speak of cancer survivors being cancer-free far less frequently. If you are among the luckiest unlucky who ... |
| 26.10.2023 | What are the 4 Pillars of Cancer Care? | Cancer remains the second most common cause of mortality in the U.S., and according to recently published data from 17 National Cancer Institute registries, younger adults are increasingly diagnosed with common cancers. Specifically, cancer... |
| 24.10.2023 | First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO | Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in the Journal of Clinical Oncology and accepted by ESMO for oral pre... |
| 19.09.2023 | A popular breast cancer genomic test underestimates risks for Black women | When a woman first learns she has breast cancer, her mind immediately floods with “what now?” questions as she grapples with how this disease will impact her life.
Unfortunately, Black women also have to ask themselves, “Will my racial heri... |
| 15.09.2023 | Enhertu recommended in EU for HER2-mutant NSCLC | Enhertu recommended in EU for HER2-mutant NSCLC
Fri, Sep 15, 2023 16:00 CET Report this content
15 September 2023
Enhertu recommended for approval in the EU by CHMP for
patients with HER2-mutant advanced non-small cell lung cancer
Recommend... |
| 06.09.2023 | Balancing Innovation and the Ethical Adoption of AI in Healthcare | Andre Esteva, Founder and CEO of ArteraAI
In recent years, the rapid advancement of artificial intelligence (AI) has created a wave of excitement and anticipation within the healthcare industry. AI has the potential to revolutionize patient... |
| 02.09.2023 | ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors | SAN DIEGO, Calif. and SHANGHAI, Sept. 2, 2023 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in p... |
| 20.08.2023 | Why OneOncology Is Adopting Verily’s Clinical Trial Management System | More than 1,300 oncology drugs are in the development pipeline, waiting to potentially embark on the long journey toward their commercial debut. This journey is usually an arduous one, made even more difficult by the mere 6% participation r... |
| 15.08.2023 | Radiation, a mainstay of cancer treatment, begins a fade-out | Every year, doctors get better tools to fight cancer. Engineered cancer-killing cells, immunotherapies, targeted drugs, and more are helping clinicians cure more patients. Increasingly, though, oncologists are trying to use less radiation, ... |
| 15.08.2023 | The best way for the NIH to reduce drug prices is to address drug spending | As STAT reported recently, the Senate Committee on Health, Education, Labor, and Pensions (HELP) has indicated that it will not consider the nomination of Monica Bertagnolli as director of the National Institutes of Health unless she pledge... |
| 09.08.2023 | Jobs in Oncology/Hematology | FDA is recruiting oncologists and hematologists to serve in the dynamic, highly challenging, and innovative atmosphere of oncology drug development and research. Who We Are
Meet Dr. Nicole Gormley, Division Director of Hematologic Malignanc... |
| 31.07.2023 | Vivek Ramaswamy wants to ‘gut’ the FDA. His claims don’t hold up to scrutiny | STAT readers know Vivek Ramaswamy from his time as the founder of the biotech conglomerate Roivant — and for his role in some of its various subsidiaries and spinoffs. Of course, the world now knows Ramaswamy for a very different reason: He... |
| 05.06.2023 | ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer | YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab ved... |
| 03.06.2023 | Cross-border ‘twinning programs’ may reduce survival disparities for childhood leukemia | CHICAGO — A few miles can mean a life or death difference to children with cancer, if those miles cross a national border. “Twinning programs” helped to reduce survival disparities in childhood acute leukemia between high-income and lower-i... |
| 31.05.2023 | Newly diagnosed cancer patients need help navigating the system | “Hey, I’m sorry to bother you, but I could really use your advice on something.”
As fellows in oncology training programs, we’re both accustomed to fielding texts, emails, and calls that start out like the above from family, friends, and ac... |
| 22.04.2023 | Financial Navigation Can Reduce the Financial Toxicity of Cancer Care | April 21, 2023, by Carmen Phillips
Several studies have now shown that financial navigation programs can help people with cancer and their caregivers save money and improve their quality of life.
Credit: National Cancer Institute
Results fr... |
| 14.04.2023 | Healthier Uses For The $5 Billion NextGen Covid-19 Funds | Paraphrasing a line miscredited to Einstein: “Insanity is repeating the same mistakes and expecting different results.” With the just announced White House $5 Billion Covid-19 NextGen Project for vaccine research and development, it seems t... |
| 10.04.2023 | Here’s a new data point for cancer patients to consider: ‘time toxicity’ | When Jeannette Cleland learned earlier this year that she could get chemotherapy at home, after dropping a particularly toxic medication, it seemed like good news.
But then Cleland, a 44-year-old Minneapolis event planner who has stage 4 pa... |
| 29.03.2023 | Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response | What You Should Know:
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases a... |
| 28.03.2023 | Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response  | What You Should Know:
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases a... |
| 19.03.2023 | In Cancer, Patient-Empowering AI Begins To Change Care, Relationships | Researchers who applied artificial intelligence applied to the doctor's notes were able to predict ... [+] survival for cancer patients with 80 to 90 percent accuracy, possibly opening the way for an app allowing patients to do this themsel... |
| 16.03.2023 | The Cancer Moonshot will never take off without economists and finance experts | In February, President Biden announced the reboot of the Cancer Moonshot and vowed to reduce cancer mortality by 50 percent in the next 25 years. It’s a goal that’s both lofty and achievable — but only if the advances in science are accompa... |
| 15.03.2023 | Study in JCO Precision Oncology shows promising results supporting the use of glycosaminoglycan profiles (GAGomes) for monitoring and predicting response in patients with mRCC | Study in JCO Precision Oncology shows promising results supporting the use of glycosaminoglycan profiles (GAGomes) for monitoring and predicting response in patients with mRCC
Wed, Mar 15, 2023 08:30 CET Report this content
Stockholm, March... |
| 28.02.2023 | Memora Health CEO Manav Sevak talks partnership with Moffitt Cancer Center | Memora Health uses AI to digitize and automate complex care workflows in spaces like oncology
Memora Health is a company using artificial intelligence to digitize and automate complex care workflows. The company partners with clinicians to ... |
| 23.02.2023 | American Cancer Society warns about potential impact of missed screenings during Covid | When the Covid-19 pandemic brought ordinary life to a halt in 2020, routine cancer screenings fell off many people’s list of priorities. Screenings for cervical, breast, and prostate cancer all dropped in the first year of the Covid-19 pand... |
| 07.02.2023 | Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing | /EIN News/ -- SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that underscore the company’s commit... |
| 07.02.2023 | Antidote and XpertPatient.com partner to empower those new to a cancer diagnosis to easily find clinical trials | Antidote and XpertPatient logos “By joining forces, we are providing those new to cancer with a more holistic view of their options, building confidence and enabling them to be true partners to their doctors during treatment planning.” - Ri... |
| 06.02.2023 | Targeted Drug Tagrisso Could Be Advance Against Lung Cancer | MONDAY, Feb. 6, 2023 (HealthDay News) -- The best treatment for a genetically driven form of lung cancer continues to show lasting benefits, a new clinical trial update shows.
Tagrisso (osimertinib) nearly doubles disease-free survival in e... |
| 06.02.2023 | Personal story leads entrepreneur to launch a startup to improve cancer care in Africa and beyond | Hurone AI founder Kingsley Ndoh. (Hurone Photo)
Seattle entrepreneur Kingsley Ndoh is driven by the memory of his aunt, who died too young of colon cancer.
A lot of things went wrong when she was sick more than ten years ago in Nigeria, sai... |
| 03.01.2023 | Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test | IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cance... |
| 03.01.2023 | Better information on sexual orientation and gender identity is needed to improve LGBTQ+ health | Over the past three years, many Americans learned more about epidemiology than they ever knew before. From Covid-19 to mpox to polio, a new generation of citizen scientists is now joining trained professionals in analyzing public health dat... |
| 28.12.2022 | Imfinzi, Imjudo approved in Japan for 3 cancers | Imfinzi, Imjudo approved in Japan for 3 cancers
Wed, Dec 28, 2022 08:00 CET Report this content
28 December 2022 07:00 GMT
Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for un... |
| 22.12.2022 | Re-engineering Cancer Clinical Trials at Scale | In his book, Applied Minds: How Engineers Think, Guru Madhavan explores the mental makeup of engineers. His framework is built around a flexible intellectual toolkit called modular systems thinking. He says that “systems-level thinking is m... |
| 19.12.2022 | Imfinzi + Imjudo recommended for approvals in EU | Imfinzi + Imjudo recommended for approvals in EU
Mon, Dec 19, 2022 08:10 CET Report this content
19 December 2022 07:10 GMT
Imfinzi plus Imjudo recommended for approval in the EU
by CHMP for the treatment of advanced liver and lung cancers
... |
